Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지

IMMUNOHISTOCHEMICAL STUDY OF P21 AND P53 EXPRESSION IN AMELOBLASTOMA

법랑아세포종에서 p21 및 p53 발현에 관한 면역조직화학적 연구

  • Shin, Dong-Joon (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Myoung, Hoon (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Hwang, Kyeng-Kyun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Kim, Myung-Jin (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University)
  • 신동준 (서울대학교 치과대학 구강악안면외과학 교실) ;
  • 명훈 (서울대학교 치과대학 구강악안면외과학 교실) ;
  • 황경균 (서울대학교 치과대학 구강악안면외과학 교실) ;
  • 김명진 (서울대학교 치과대학 구강악안면외과학 교실)
  • Published : 2003.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

The p53 protein was discovered in 1979 as cellular 53-kD nuclear phosphoprotein bound to the large transforming antigen of SV40 virus. $P21^{WAF1/CIP1}$, which has been described as the critical downstream mediator of p53, is known to suppress DNA replication and arrest the G1 cell cycle by quaternary complex with cyclin D, cyclin-dependent kinase(CDK) and proliferating cell nuclear antigen(PCNA). In these days, some studies shows that the p21 can be induced by independent pathways. There are various reports about the expression of p21 (67%.82.4%) in oral squamous cell carcinoma. But these studies are mostly done in malignant tumor not in benign tumor. So we decided to study the expression of p21 in ameloblastoma and the relationship between p53 and p21 as a downstream mediator of p53 in ameloblastoma. We investigated the expression of p21 and p53 with the method of immunohistochemistry. We selected 30 cases of ameloblastoma tissue blocks (acanthomatous type: 5 cases, follicular type: 8 cases, plexiform type: 17 cases) imbedded in paraffin. We used 30 cases of normal gingival tissues and 30 cases of squamous cell carcinoma tissues (SCC) respectively and compared their results with those of ameloblastoma. We made slides with the streptavidin-biotin methods and used monoclonal antibody DO-7 (Novocastra, Newcastle, United Kingdom) as p53 antibody and monoclonal antibody M7202 (DAKO, California, U.S.A.) as p21 antibody. We used Pearson's correlation coefficient to analyse the relationship. The results were as follows: 1. p21 was expressed in ameloblastoma about 30% and this is lower than that of normal gingiva and SCC. 2. In normal gingiva and ameloblastoma, p21 expression was correlated with p53 expression. 3. In SCC, p21 were expressed about 83.3% and this is more than that of p53. But there was no correlation between p21 and p53 expression. We confirmed p21 expression and relation with p53 in ameloblastoma. But, to confirm the function of p21, more studies about p21 expression in malignant ameloblastoma and ameloblastic carcinoma are needed.

Keywords

References

  1. Lu S, Tiekso J, Hietanen S, Syrja¨nen K, HavuV. K, Syrj nen S. Expression of Cell-cycle Proteins p53, p21 (WAF-1), PCNA and Ki-67 in Benign, Premalignant and Malignant Skin Lesions with Implicated HPV Involvement. Acta Derm Venereol 79:268-273, 1999. https://doi.org/10.1080/000155599750010634
  2. Kapranos N, Stathopoulos G. P, Manolopoulos L, Kokka E, Con. Papadimitriou, Bibas A, Yiotakis J, Adamopoulos G. p53, p21 and p27 Protein Expression in Head and Neck Cancer and their Prognostic Value. Anticancer Research 21:521-528, 2001.
  3. Annette Schmider, Conway Gee, Wolfgang Friedmann, Jason J. Lukas, Michael F. Press, Werner Lichtenegger, Angela Reles. p21(WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecologic Oncology 77:237-242, 2000.
  4. Ng I. O. L, Lam K. Y, Ng M, Regezi J. A. Expression of p21/waf1 in oral squamous cell carcinomas - correlation with p53 and mdm2 and cellular proliferation index. Oral Oncology 35:63-69, 1999.
  5. Yook J. I, Kim J. Expression of p21(WAF1/CIP1) is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncology 34:198-203, 1998. https://doi.org/10.1016/S1368-8375(97)00091-2
  6. Agarwal S, Mathur M, Shukla N. K, Ralhan R. Expression of cyclin dependent kinase inhibitor p21waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. Oral Oncology 34:353-360, 1998. https://doi.org/10.1016/S1368-8375(98)00021-9
  7. Xin Li, Ai-Min Hui, Tadatoshi Takayama, Xing Cui, Yazhou Shi, Masatoshi Makuuchi. Altered p21waf1/cip1 expression is associated with poor prognosis in extrahepatic bile duct carcinoma. Cancer Letters 154:85-91, 2000. https://doi.org/10.1016/S0304-3835(00)00383-9
  8. Ozcelik H, Mousses, Andrulis I. L. Low levels of expression of an inhibition of cyclindependent kinases(CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res 1:907-912, 1995.
  9. Shin D. M, Lee J. S, Lippman S. M. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:519-529, 1996.
  10. van Oijen M. G. C. T, Tilanus M. G. J, Medema R. H, Slootweg, P. J. Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J Oral Pathol Med 27:367-37, 1998.
  11. Michieli P, Chedid M, Lin D, Pierce J. H, Mercer W. E, Givol D. Induction of WAF/cip1 by a p53-independent pathway. Cancer 54:3391-3395, 1995.
  12. Datto M. B, Li Y. Panus J. F, Howe D. J, Xiong Y, Wang X. F. Transforming growth factor $\beta$induces the cyclin-dependent kinase inhibitor p21 through p53-independent mechanism. Proc Natl Acad Sci USA 92:5545-5549, 1995.
  13. Costa M. J, Hansen C. L, Walls J. E, Scudder S. A. Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasm: p21WAF/CIP1 predicts survival and good response to platinin-based chemotherapy. Hum Pathol 30:640-647, 1999.
  14. Tatemoto Y, Osaki T, Yoneda K, Yamamoto T, Veta E, Kimura T. Expression of p53 and p21 proteins in oral and squamous cell carcinoma: Correlation with lymph node metastasis and response to chemotherapy. Pathol Res Pract 194:821-830, 1998. https://doi.org/10.1016/S0344-0338(98)80084-8
  15. Tahara E. Molecular biology of gastric cancer. World J Surg 19:484-490, 1995. https://doi.org/10.1007/BF00294705
  16. Staffan Jahnson, Mats G. Karisson. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 89:619-629, 2000. https://doi.org/10.1002/1097-0142(20000801)89:3<619::AID-CNCR18>3.0.CO;2-4
  17. Steven A. Ahrendt, Heather M. Brown, Richard A. Komorowski, Yong-ran Zhu, Stuart D. Wilson, Beth A. Erickson, Paul S. Ritch, Henry A. Pitt, Michael J. Demeure. p21waf1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery 128:520-528, 2000.
  18. Ceccarelli C, Santini D, Chielco P, Lanciotti C, Taffurelli M, Paladini G, Marrano D. Quantitive p21waf1/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. Int J Cancer 95:128-34, 2001. https://doi.org/10.1002/1097-0215(20010320)95:2<128::AID-IJC1022>3.0.CO;2-D
  19. Kumamoto Hiroyuki, Kimi Kenji, Ooya Kiyoshi. Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med 30(5):309-315, 2001. https://doi.org/10.1034/j.1600-0714.2001.300509.x
  20. Chang Kuo-Wei, Lin Shu-Chun, Kwan Po-Cheung, Wong Yong-Kie. Association of aberrant p53 and p21waf1 immunoreactivity with the outcome of oral verrucous leukoplakia in Taiwan. J Oral Pathol Med 29, 56-62, 2000.
  21. Sandra F, Mitsuyasu T, Nakamura N, Shiratsuchi Y, Ohishi M. Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncology 37:193-198, 2001. https://doi.org/10.1016/S1368-8375(00)00079-8
  22. Kumamoto Hiroyuki. Detection of apoptosisrelated factors and apoptotic cells in ameloblastomas: analysis by immunohistochemistry and an in situ DNA nick end-labelling method. J Oral Pathol Med 26:419-442, 1997. https://doi.org/10.1111/j.1600-0714.1997.tb00242.x